**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a case series, three men aged 53−74 years were described, who developed heparin-induced thrombocytopenia and thrombosis during treatment with heparin. Additionally, two of the three men received off-label treatment with hydroxychloroquine and tocilizumab for COVID-19 and one man showed lack of efficacy on nitric oxide during vasodilator therapy in COVID-19 \[*time to reactions onset not stated; not all dosages, routes and outcomes stated*\].

Case 1: The 70-year-old man tested positive for COVID-19 on 16 March 2020, following which he was admitted. On admission, he was intubated, and he started receiving ceftriaxone and azithromycin. He was also started on SC heparin \[unfractionated heparin\] 5000 units twice a day as prophylaxis for deep venous thrombosis. Thereafter, he received hydroxychloroquine (off-label) for 5 days. On hospital day 5 (HD), worsening of oxygenation and ventilation was observed, and he responded to cisatracurium besilate \[cisatracurium\] and prone positioning. He started receiving tocilizumab (off-label). From HD9−17, he received remdesivir. From HD17, his condition worsened with adult respiratory distress syndrome. Despite receiving prophylaxis with heparin, he developed pulmonary emboli. CT scan showed subsegmental and segmental pulmonary emboli in the right middle and upper lobe and left lower lobe. He started receiving heparin infusion at 18 units/kg/h. A gradual decrease in platelets was observed from HD13. As his 4T score was 6, HIT was suspected. A test for anti-platelet factor (PF)-4/heparin antibody was performed, and heparin was switched to bivalirudin. The following day, his anti-PF4/ heparin antibody returned positive, which was indicative of HITT. A confirmatory serotonin release assay (SRA) was ordered. Over the next 16 hours, his ventilator and oxygen requirements increased with progressive hypotension, for which he received vasopressin and norepinephrine. He also received a trial of nitric oxide, which was unsuccessful. Hence, tenecteplase was started. Due to clinical deterioration, comfort-oriented care was requested by his wife. Eventually, he died \[*exact cause of death not stated*\]. Several days later, SRA tests from HD18 returned positive.

Case 2: The 74-year-old man was admitted due to progressive cough, fatigue dyspnoea and hoarseness for 2 weeks. He was started on various antibiotics and enoxaparin sodium (deep vein thrombosis prophylaxis). A nasopharyngeal swab for COVID-19 returned positive. Due to a prolonged QTc interval, azithromycin was switched to doxycycline. Further, his condition worsened to adult ARDS, resulting in transfer to the ICU and intubation. On HD3, he developed hypotension, and he started receiving vasopressin, norepinephrine and hydrocortisone. Pulmonary embolism was suspected, but chest CT scan was not performed due to COVID isolation. Doppler ultrasound of bilateral lower-extremities showed no evidence of thrombosis. He started recieiving empirical treatment with heparin infusion at 18 units/kg/h (platelet count of 158 000 /mm^3^). Due to guaiac-positive non-bloody stool, heparin infusion was reconsidered. CT scan showed no thromboembolic disease. Heparin treatment was changed to SC weight-adjusted heparin 7500 units twice a day. Due to prolonged QTc, positive quantiferon test for latent tuberculosis infection and and pressor requirements, he was not considered as candidate for antiviral therapy. On HD9, decrease in platelet count to 8 7000 /mm^3^ from 16 5000 /mm^3^ (on HD 6). His 4T score was 4, and heparin was discontinued. Ultrasound examination of four extremities and anti-PF4/heparin antibody test was ordered. Due to pending results and to decrease the contact with blood, he started receiving fondaparinux sodium \[fondaparinux\]. On HD10, his anti-PF4/heparin antibody test returned positive with an optical density of 1.3. Ultrasound showed left basilica, right cephalic and left cephalic thrombosis, which was consistent with HITT. Fondaparinux sodium was switched to bivalirudin. On HD14, SRA returned negative. His GI bleeding precluded anticoagulation, and bivalirudin was discontinued. Over following 3 weeks, he developed worsening renal and hepatic dysfunction. On HD34, he died \[*exact cause of death not stated*\].

Case 3: The 53-year-old man presented to the emergency department with palpitations, chest pain and productive cough on 25 March 2020. Examination revealed atrial fibrillation (AF). His heart rate improved with metoprolol treatment, and for AF, he started receiving heparin infusion at 12 units/kg/h. He also started receiving furosemide, ceftriaxone and azithromycin. He was admitted to a telemetry isolation unit, following which his nasopharyngeal swab for COVID testing returned positive. He was treated with hydroxychloroquine (off-label). Further, his condition worsened with ARDS, and he was intubated. His ARDS was treated with cisatracurium besilate \[cisatracurium\]. On HD11, decrease in platelet count from 22 1000 /mm^3^ to 5 3000 /mm^3^ over 2 days was observed. He also developed skin blisters with black eschars, which was indicative of of skin necrosis. His 4T score was 6, and heparin treatment was changed to argatroban. Test for anti-PF4/heparin antibodies was also positive (optical density: 0.48), indicative of HTT. Over the next 5 days, his platelet count rebounded with improvement from a respiratory standpoint. On HD17, his SRA returned negative. His anticoagulation therapy was changed to apixaban. On HD37, he was transferred to rehabilitation after 2 consecutive negative COVID swabs.
